Study S000424

Effects of Liraglutide on Hemodynamic Parameters in Patients With Heart Failure

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02490176
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: UNKNOWN
Enrollment: 50
Start: 2015-07
Primary completion: 2016-07
Lead sponsor: Chinese PLA General Hospital
Conditions: Heart Failure
Interventions: DRUG:liraglutide; DRUG:placebo
Results posted: FALSE

Registered primary outcomes

a change in cardiac output measured by pulse indicator continuous cardiac output (PiCCO) technology [7 days after treatment]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023502	Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Lønborg J, European heart journal	2012	Randomized trial	PMID 21920963 DOI	registry reference BACKGROUND:21920963
R0021038	GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Noyan-Ashraf MH, Diabetes	2009	Preclinical	PMID 19151200 DOI	registry reference BACKGROUND:19151200
R0025460	Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. Timmers L, Journal of the American College of Cardiology	2009	Randomized trial	PMID 19195607 DOI	registry reference BACKGROUND:19195607